title: Increased plasma levels of thioredoxin-1 in patients with first episode psychosis and long-term schizophrenia.
abstract: Excessive level of radicals and/or dysfunctional antioxidant response, oxidative stress, is implicated in the pathogenesis of schizophrenia. A condition of oxidative stress has been detected in the brain, peripheral tissues and fluids including plasma. Plasma thioredoxin-1 (Trx1) is well characterized and a putative marker for oxidative stress and recently shown to be increased in plasma at the onset of schizophrenia. The present study aimed to explore whether Trx1 can be used as a marker to identify schizophrenic patients at the time-point when patients have their first episode of psychosis as compared to patients with long-term schizophrenia and mentally healthy patients, respectively. Plasma samples obtained from 18 patients at first episode of psychosis, from 49 long-term schizophrenic patients and from 20 mentally healthy controls (admitted with minor physical injury to the general ward) where analyzed by ELISA for Trx1. The patients with first episode of psychosis were diagnosed at least 6 months later and shown to constitute various psychotic syndromes, including schizophrenia, or affective disorder. The concentration of Trx1 in the patients with first episode of psychosis was 1.5 ± 1.0 ng/ml and 0.8 ± 0.6 ng/ml in controls. In the long-term schizophrenic patients the plasma concentration was 1.5 ± 0.7. The differences between the groups of acute psychotic or long-term schizophrenia patients to controls were significant (p < 0.016 and p < 0.001, respectively). Our data indicate that Trx1 may not be used as an early marker to identify schizophrenic patients in a mixed population of first episode psychotic patients. Further, Trx1 did not discriminate with reliable accuracy patients with psychotic disorder from mentally healthy controls on an individual basis due to overlap in levels of Trx1. However, our observations show that psychotic patients in general are in a significant long-term condition of oxidative stress, with possible implications for the profound morbidity and mortality found in this patient population.
authors: Karolinska Institute, Department of Clinical Neuroscience, Section of Psychiatry at Karolinska, University Hospital Huddinge, SE-141 86 Stockholm, Sweden.
authors: Björn
authors: B
authors: Owe-Larsson
authors: Karin
authors: K
authors: Ekdahl
authors: Tobias
authors: T
authors: Edbom
authors: Urban
authors: U
authors: Osby
authors: Håkan
authors: H
authors: Karlsson
authors: Christer
authors: C
authors: Lundberg
authors: Mathias
authors: M
authors: Lundberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers; D002908:Chronic Disease; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D012559:Schizophrenia / Q000097:blood*; D012565:Schizophrenic Psychology; D013879:Thioredoxins / Q000097:blood*; D055815:Young Adult
chemical_list: D015415:Biomarkers; D013879:Thioredoxins